Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Eli Lilly and Co (LLY) has agreed to acquire POINT Biopharma Global Inc (PNT) for $12.50 per share in cash, totaling approximately $1.4 billion. The purchase price represents a premium of about 87% to POINT's closing stock price on Oct. 2, 2023. PNT shares are up 84.35 at $12.32, and LLY stock is down 0.22% at $537.13 during the premarket session.
October 03, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's stock is down 0.22% following the announcement of the acquisition of POINT Biopharma.
The acquisition announcement has led to a slight decrease in Eli Lilly's stock price. This could be due to the significant cash outlay for the acquisition, which may impact the company's short-term financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
POINT Biopharma's stock is up 84.35 at $12.32 following the announcement of its acquisition by Eli Lilly.
The acquisition announcement has led to a significant increase in POINT Biopharma's stock price. This is likely due to the premium price that Eli Lilly has agreed to pay for the shares.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100